Search clinical trials for: Dabigatran

Total 294 results

Boehringer Ingelheim

Completed

Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects

Healthy

Japan
Centre Hospitalier Universitaire de Saint Etienne
Groupe de Recherche sur la Thrombose

Completed

Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin (IMAGINE)

Healthy

France
Boehringer Ingelheim

Completed

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects

Healthy
Boehringer Ingelheim

Completed

Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects

Healthy
Boehringer Ingelheim

Completed

A Study of BIBR 1048 in Prevention of Venous Thromboembolism in Patients With TKR Surgery.

Venous Thrombosis | Arthroplasty, Replacement, Knee

Japan
Boehringer Ingelheim

Completed

Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa

Hemorrhage | Atrial Fibrillation

United States
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

Thromboembolism | Arthroplasty, Replacement, Knee

United States, Canada, Mexico, United Kingdom
Boehringer Ingelheim

Completed

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

Atrial Fibrillation

United States, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, Malaysia, Netherlands, Norway, Phili... and more
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment

Renal Insufficiency
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Healthy
Nova Scotia Health Authority
Dalhousie University; Université de Montréal; Capital Health, Canada

Completed

An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients

Blood Coagulation Disorders

Canada
Doasense GmbH

Active, not recruiting

Pharmacokinetics and Point of Care Testing of Direct Oral Anticoagulants Subjects (PHAPOCU)

Anticoagulant Therapy

Germany
Boehringer Ingelheim
Uppsala University; Population Health Research Institute

Completed

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Stroke | Atrial Fibrillation

United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Republic of, Malaysia, Mexico, N... and more
Boehringer Ingelheim

Completed

Drug Interaction Study With Dabigatran Etexilate and Dronedarone in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Dabigatran Etexilate in Patients With Mechanical Heart Valves (RE-ALIGN)

Heart Valve Diseases

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland, Sweden
Boehringer Ingelheim

Terminated

Follow on Study From RE-ALIGN

Thromboembolism | Heart Valve Prosthesis

Belgium, Canada, Czech Republic, Denmark, France, Germany, Netherlands, Norway, Poland
Centre Hospitalier Universitaire de Saint Etienne

Completed

Effect of Inhibitors of the Proton Pump on Intestinal Transporters (BIPP)

Healthy

France
Boehringer Ingelheim
Health ResearchTx, LLC (HRTX); inVentiv Health Clinical (iVH); United States...

Completed

The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis

Atrial Fibrillation

United States
University Hospital, Grenoble

Completed

Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics (REVNEWANTICO)

Venous Thromboembolism

France
Ural State Medical University
Boehringer Ingelheim

Unknown

Evaluation of Abbreviated Versus Conventional Course of Dabigatran Etexilate Before Electric Cardioversion in Patients With Atrial Fibrillation (RE-SOUND Study) (RE-SOUND)

Atrial Fibrillation

Russian Federation
Boehringer Ingelheim

Completed

Safety and Tolerability of Dabigatran Etexilate in Adolescents

Venous Thromboembolism

Canada
Boehringer Ingelheim

Completed

Bioequivalence of Two Different Capsule Types of Dabigatran

Healthy

Germany
Boehringer Ingelheim

Terminated

Long-term, Open-label Follow-up Treatment of Patients With A-fib Who Have Been Previously Treated With BIBR 1048

Stroke | Atrial Fibrillation

United States, Denmark, Netherlands, Sweden
Boehringer Ingelheim

Completed

Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age

Venous Thromboembolism

Canada, France, Russian Federation
Boehringer Ingelheim

Completed

Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.

Healthy
Lawson Health Research Institute
Boehringer Ingelheim

Completed

DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation (DAPPARAF)

Atrial Fibrillation

Canada
Boehringer Ingelheim

Completed

A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)

Thromboembolism

Spain, Germany, India, Italy, Netherlands, Portugal, France, Poland, Russian Federation
Boehringer Ingelheim

Completed

Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects

Healthy

Japan
Irina Ermolaeva

Recruiting

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD (RE-ELECT)

Chronic Kidney Diseases | Atrial Fibrillation | T2DM (Type 2 Diabetes Mellitus)

Russian Federation
Boehringer Ingelheim

Completed

Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function

Atrial Fibrillation

United States
Boehringer Ingelheim

Recruiting

A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot (DaPaR)

Venous Thromboembolism

Spain, Germany, Netherlands, Czechia, Finland, Sweden
Boehringer Ingelheim

Terminated

Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery

Venous Thromboembolism | Arthroplasty, Replacement

Austria
Boehringer Ingelheim

Completed

Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

Venous Thromboembolism | Secondary Prevention

United States, Norway, Canada, Belgium, Thailand, Italy, Germany, Turkey, Austria, Hungary, Czechia, Taiwan, Israel, Brazil, Denmark, France, Lithuania, Mexico, Russian Federation, Sweden, Switzerland, Ukraine
Boehringer Ingelheim

Completed

Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.

Renal Insufficiency, Chronic

Netherlands
Korea University

Unknown

Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk

Atrial Fibrillation | Thromboembolism
Boehringer Ingelheim

Completed

Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis

Cardiovascular Diseases | Kidney Failure, Chronic

Germany
Capital Medical University

Unknown

The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis

Cerebral Venous Thrombosis

China
Boehringer Ingelheim

Withdrawn

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Venous Thromboembolism

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers

Healthy

Germany
Merck KGaA, Darmstadt, Germany

Completed

Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate

Healthy

Germany
Ross Leighton
Nova Scotia Health Authority

Withdrawn

A Cohort Study With 100 Subjects Having a Primary Total Knee Replacement, Taking Pradax Post Discharge for Ten Days

Thromboembolism

Canada
Boehringer Ingelheim

Completed

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)

Atrial Fibrillation

Spain, United States, United Kingdom, Canada, Germany, Italy, Japan, Belgium, Netherlands, France, Russian Federation
Kyunghee University Medical Center

Unknown

Pleotropic Effect of New Oral Anticoagulants

Atrial Fibrillation

Korea, Republic of
Boehringer Ingelheim

Completed

Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate

Arthroplasty, Replacement | Prevention of Venous Thromboembolism | Moderate Renal Impairment (CrCl 30-50 mL/Min)

Austria, Canada, Czechia, Finland, Netherlands, Sweden
Boehringer Ingelheim

Completed

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Hepatic Insufficiency

3

Subscribe